PTSD severity

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51